Molecular therapy for acute myeloid leukaemia

Catherine C. Coombs, Martin S. Tallman, Ross L. Levine*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

97 Scopus citations

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous disease that is, in general, associated with a very poor prognosis. Multiple cytogenetic and molecular abnormalities that characterize different forms of AML have been used to better prognosticate patients and inform treatment decisions. Indeed, risk status in patients with this disease has classically been based on cytogenetic findings; however, additional molecular characteristics have been shown to inform risk assessment, including FLT3, NPM1, KIT, and CEBPA mutation status. Advances in sequencing technology have led to the discovery of novel somatic mutations in tissue samples from patients with AML, providing deeper insight into the mutational landscape of the disease. The majority of patients with AML (>97%) are found to have a clonal somatic abnormality on mutational profiling. Nevertheless, our understanding of the utility of mutation profiling in clinical practice remains incomplete and is continually evolving, and evidence-based approaches to application of these data are needed. In this Review, we discuss the evidence-base for integrating mutational data into treatment decisions for patients with AML, and propose novel therapeutic algorithms in the era of molecular medicine.

Original languageEnglish (US)
Pages (from-to)305-318
Number of pages14
JournalNature Reviews Clinical Oncology
Volume13
Issue number5
DOIs
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Molecular therapy for acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this